Short-course antibiotics for non-severe childhood pneumonia: similar failure, much better adherence

Design

Systematic review and random-effects meta-analysis of 10 randomised trials

Population

8,970 immunocompetent children under 18 with non-severe community-acquired pneumonia

Primary outcome

Treatment failure, relapse and non-adherence with 5 days or less vs more than 5 days

Effect

Failure RR 1.07 (95% CI 0.93 to 1.24); relapse RR 1.04 (0.72 to 1.49); non-adherence RR 0.35 (0.24 to 0.50)

This systematic review and meta-analysis pooled ten randomised trials including 8,970 immunocompetent children under 18 with non-severe community-acquired pneumonia. Short courses (5 days or less) were compared with longer therapy (over 5 days). Risk of bias was assessed with ROB 2.

Treatment failure did not differ (RR 1.07, 95% CI 0.93 to 1.24; I-squared 3%), nor did relapse (RR 1.04, 0.72 to 1.49). Non-adherence to the antibiotic was much lower with short courses (RR 0.35, 0.24 to 0.50; I-squared 54%), the most consistent difference. Adverse events were comparable (RR 0.71, 0.36 to 1.40), though heterogeneity was high (I-squared 81%).

The authors state the meta-analysis was not designed to formally prove non-inferiority. Trials differed in drugs and settings, and the population was non-severe pneumonia in immunocompetent children. Current guidance in your country should guide the choice of duration.

• For non-severe pneumonia in an otherwise well child, consider a course of 5 days or less in line with local guidance.
• Shorter courses were associated with far fewer missed doses (RR 0.35).
• This does not apply to severe pneumonia, empyema, or immunocompromised children.
• Review the child if fever or breathing difficulty persists beyond expected course.
• Advise parents to complete the course and explain the stop date clearly.

Why it matters

Children miss doses more often on long courses, so shorter courses may deliver more of the intended treatment.

Don't overread it

The review was not designed to prove non-inferiority, and applies only to non-severe pneumonia in immunocompetent children.

The statistics, in plain English

A risk ratio of 1.07 with an interval of 0.93 to 1.24 means treatment failure was about the same, but the interval allows up to 24% more failure, so equivalence is not proven. The adverse-event result has high heterogeneity (I-squared 81%), so treat it with caution.

Read the rest in the app

You have read your two free briefings this month. The app carries all 27 specialties, every morning, free — and this finding is waiting in it.

Get Daily Doctor — free

Scan to keep reading on your phone. No account needed to start.